These results have sometimes provided hints into disease pathobiology, [103] a GWAS implicated the IL-12/IL-23 pathway in the development of CD, which supported subsequent clinical trials for drugs targeting the IL-12/IL-23 pathway [104]. This evidence concerns the gene IL23A and Cowden disease.